Healing Hands is a collection of art by caregivers made to process their mentally exhausting jobs. Photo by Tre’Voy Kelly & Company

Caring for the sick can be mentally exhausting. A new gallery of artwork at Houston’s Health Museum, created by caregivers including family members, nurses, and others in the care delivery sector, highlights these challenges.

“This program came to fruition thanks to the generous support of Unlikely Collaborators, who helped build the infrastructure for arts programming at The Health Museum,” Rose Tylinksi, the Museum’s Healing Arts Manager, tells CultureMap. “The Museum had already begun integrating art into their exhibits and community outreach with the focus on Human Health.

"Mental health and healing are important parts of human health, so we wanted to incorporate a program that impactfully addressed this through the intersection of the arts, medicine, and culture," she continues. "The arts, including music, dance, painting, writing, and more, are potent drivers of health and healing, fostering mindfulness, expression, and community. In fact, the health benefits of participating in the arts are comparable to those of regular exercise.”

“Healing Hands: A Collection of Caregiver Expressions on Mental Wellness” marks the museum’s further expansion into the arts, alongside their renowned interactive science exhibits focused on the human body and medical technology. Tylinski has organized workshops, "Paint and Process" events, and other gatherings to help caregivers articulate their struggles.

One example from the gallery is a series of short poems written by a caregiver that explores the various difficult conversations the creator often has with patients. Writing and reading poetry is a common method of helping doctors, nurses, and other caregivers process their experiences. Studies have shown that creating poems can ease feelings of grief and loneliness, both often associated with caregiving.

“It is designed to speak both to the struggles and wellness of our mental health,” says Tylinksi. “The art tells us about the fears, joys, and sacrifices that come with taking care of others. Art is used as a tool to process those experiences.”

Other pieces on display involve traditional visual art pieces.

“Healing Hands” will be on display at the Health Museum through February 2025 and is included in general admissions. For those interested in participating as artistic creators, keep an eye on the Health Museum website for announcements about workshops and events related to the creation of the art.

Founded in 1969, the Health Museum is a unique and quirky institution that consistently offers interesting explorations of the physical and mental human condition. It is the only Smithsonian-affiliated museum in the Museum District and provides experiences like allowing children to crawl through a giant colon to learn about the digestive system and interact with video game versions of humanity’s internal fauna. Despite its often whimsical nature, the Health Museum maintains a first-rate collection and consistently offers intriguing exhibits.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”

Houston energy hub opens new fundraising cohort to fuel startups

Apply Now

EnergyTech Cypher has opened applications for its second Liftoff fundraising program.

Applications close May 20 for the 10-week virtual fundraising sprint. The program is geared toward energy and climatech founders preparing to raise their first institutional round. It will cover fundraising requisites, like pitch materials, term sheet negotiation and round closing, according to a release from EnergyTech Cypher.

The program kicks off June 1 and runs every Monday from 1-3 p.m. CST. It will conclude with an in-person capstone simulation in Houston on August 3, where founders will work to close a mock round.

Jason Ethier, EnergyTech Cypher founder and CEO, will lead the program with Payal Patel, an EnergyTech fellow and entrepreneur in residence.

The program is available through Cephyron, EnergyTech Cypher's new investor relationship management platform, built specifically for energy and climatech founders. Users must have a Cephyron Boost membership to participate in the Liftoff program.

The Cephyron IRM app recently went live and is available to founders at any point in their fundraising process, according to the news release. The platform aggregates investor data, tracks market signals and delivers curated weekly recommendations.

EnergyTech Cypher launched Liftoff last year. The inaugural cohort included 19 startups, including Houston-based AtmoSpark Technologies, The Woodlands-based Resollant and others. Each participant closed at least one fundraising deal, according to EnergyTech Cypher.

EnergyTech Cypher rebranded from EnergyTech Nexus earlier this year. It also launched its CoPilot accelerator in 2025. The inaugural group presented its first showcase during CERAWeek last month.

EnergyTech Cypher's annual Pilotathon Pilot Pitch and Showcase applications also opened this month. Find more information here.

---

This article originally appeared on EnergyCaptialHTX.com.